U.S. FDA Move “Beyond Our Borders” Begins With China
This article was originally published in PharmAsia News
Executive Summary
Congressional concerns over inspection oversight in the midst of a heparin safety scare have not dampened FDA's efforts to highlight its new overseas initiative, "FDA Beyond Our Borders.